Chronic Pain Clinical Trial
— DOLORTRATPSIOfficial title:
Efficacy of Mindfulness-based Pain Management in Patients With Chronic Pain With and Without Fibromyalgia
NCT number | NCT03992612 |
Other study ID # | PI2018162 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 1, 2019 |
Est. completion date | June 30, 2021 |
Verified date | March 2022 |
Source | University of the Basque Country (UPV/EHU) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Today, one of the most important challenges of the health system is the attitude towards chronic disorders. That implies changing from a health structure established for the treatment of acute diseases to a continued care system. In this sense, the approach of chronic pain, of non-oncological origin, supposes an important care challenge, to which this project wishes to respond. Chronic pain affects one of every Europeans (19%), and has a prevalence of 11% in Spain, being one of the most important causes of medical consultation and is associated with high personal, social and economic costs. For example, in 2017 it was calculated that it has an economic impact of between 1.7 and 2.1% of Spain's GDP. Referred to the psychological consequences of the disease, it has been found that 42% of people who have chronic pain suffer insomnia, a 40% anxiety, and 24% depressive symptoms. Hence the importance of implementing evidence-based psychological treatments along with their treatment as usual The main objective is comparing the efficacy of mindfulness-based pain management (MBPM), together with the usual medical treatment, in patients diagnosed with chronic pain, with and without comorbid fibromyalgia. Specific objectives are: 1. To study the sociodemographic and clinical profile of patients with chronic pain, with and without fibromyalgia. 2. Define the characteristics of patients who are in the different stages of the disease: stage 1 (less than two years since diagnosis); stage 2 (between 2 and 4 years); stage 3 (between 5 and 8 years), and stage 4 (more than 8 years). 3. Check the effectiveness of psychological therapies MBPM depending on the presence of fibromyalgia. 4. Check the effectiveness of the psychological treatment in function of the stage of the disease. Method: A quasi-experimental design of two groups will be used. Patients will be assigned to experimental group: 50 subjects will receive MBPM and control group 40 subjects, 3-months wait list, after which time they will also receive MBPM. All the participants will be assessed in the baseline; at the end of the treatment; and in the 1, 3, 6 and 12 months follow-ups. Group 2 (waiting list) will be assessed in the baseline, and re-assessed before starting the treatment; at the end of the psychological therapy; and in the 1, 3, 6 and 12 months follow-ups.
Status | Completed |
Enrollment | 112 |
Est. completion date | June 30, 2021 |
Est. primary completion date | January 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Be able to complete the assessment protocol - Suffer from chronic non-oncological pain, lasting longer than 6 months - Not being receiving psychological treatment - Sign the informed consent Exclusion Criteria: - Present a cognitive impairment, such as a dementia - Present a diagnosis of a psychotic disease, bipolar disease or additive disease |
Country | Name | City | State |
---|---|---|---|
Spain | University of Basque Country | San Sebastián | Guipuzcoa |
Lead Sponsor | Collaborator |
---|---|
University of the Basque Country (UPV/EHU) |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Client Satisfaction Questionnaire | This scale assesses clients satisfaction with the treatment through 8 items, using a Likert scale from 0 to 4. (Larsen et al., 1978) | end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41) | |
Primary | Change in Lattinen Index- IL | It is a scale with five items to assess variables associated with pain: frequency, intensity, disability, drugs usage and sleep problems. These are assessed by a Likert scale of 0 to 4, in order to explain the discomfort that pain generates. (Gonzalez-Escada, 2012) | base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41) | |
Secondary | Change in the Fibromyalgia Impact Questionnaire- FIQ | its a 10 item scale that assesses the impact of the disease. The first item evaluates the interference of the disease in skills such as home care and work. The second item assesses how they felt last week; the third item values the days of last week that the disease prevented him from performing his usual tasks. Finally, the fourth item assesses the interference caused by pain and other items of the disease. It will only be completed by patients diagnosed with fibromyalgia. (Esteve et al., 2007) |
base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41) | |
Secondary | Change in the Listado de Sintomas Breve- LSB-50 | it is composed of 50 items, which are rated on a Likert scale from 0 to 4, depending on the level of discomfort caused by each item to the subject. it includes two scales of validity, three general indices, clinical scales (psychoreactivity, hypersensitivity, obsession, anxiety, hostility, somatization, depression, and sleep disturbances) and a psychological risk index. (de Rivera & Abuin, 2012) | base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41) | |
Secondary | Change in the Short Form 12 Health Survey- SF-12 | It assesses a patient's health perception in 12 areas like physical function, physical role, body pain, general health, vitality, social function, emotional role, and mental health. It is completed with Likert type response options from 3 to 5 points.(Schmidt et al., 2012) |
base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41) | |
Secondary | Change in Cuestionario de afrontamiento del dolor- CAD-R | It consists of 31 items related to the strategies that the patient performs when suffer pain. The strategies are valued from 1 (never use) to 5 (always use). The items are grouped into the following factors: religion, catharsis, distraction, information search, self-control, and self-affirmation. (Soriano & Monsaslve, 2002) | base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41) | |
Secondary | Change in Connor-Davison Resilience Scale- CDRISC | The CD-RISC scale assesses resilience. Consist in 25 items and the subject has to indicate what extent each of the statements has been true, in his case, during the last month on a scale ranging from 0 (not true at all) to 4 (almost always true). Fernández-Lansac & Soberón, 2014) | base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41) | |
Secondary | Change in Inventaire of negative thoughts in response to pain- INTRP | This questionnaire assesses the presence of negative thinking in response to pain. It consists of 21 items distributed in 5 factors: general negative thoughts, negative social thoughts, thoughts of disability, thoughts of lack of control, and thoughts of self-blame (Cano & Rodriguez, 2002) | base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41) | |
Secondary | Change Pain Catastrophizing Scale- PCS | The scale evaluates through 13 items the thoughts and feelings related to the experiences of pain. It is divided into three subscales, scored from 0 (never) to 4 (always), rumination, desperation, and magnification (Lami et al., 2013) | base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41) | |
Secondary | Change in Chronic Pain Acceptance Questionnaire- CPAQ | The scale evaluates strategies of the pain experience. It consists of 20 items, scored from 0 (never true) to 6 (always true), from which three scores are obtained: involvement in activities, openness to pain, and total punctuation. | base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|